Gila monster Gila monster The Gila monster ("Heloderma suspectum", ) is a species of venomous lizard native to the southwestern United States and northwestern Mexican state of Sonora. A heavy, typically slow-moving lizard, up to long, the Gila monster is the only venomous lizard native to the United States and one of only two known species of venomous lizards in North America, the other being its close relative, the Mexican beaded lizard ("H. horridum"). Although the Gila monster is venomous, its sluggish nature means it represents little threat to humans. However, it has acquired a fearsome reputation, and is sometimes killed despite
Mexican beaded lizard (swelling), weakness, sweating, and a rapid fall in blood pressure. Beaded lizards are immune to the effects of their own venom. Some compounds in its venom have been shown to have pharmacological properties relating to the possible treatment of diabetes, Alzheimer's disease, and even HIV. One compound, a hormone named exendin-3, is marketed by Amylin Pharmaceuticals as the drug exenatide. A study in 1996 revealed that it binds to cell receptors in breast cancer cells and may stop the growth of lung cancer cells. The beaded lizard becomes sexually mature at six to eight years and mates between September and